SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Inclusion Criteria:

• Pathologically confirmed and documented cutaneous melanoma- CM patients (includingacral melanoma) with unresectable or metastatic disease

• HLA-A*02:01 positive

• Adequate selected organ function per protocol

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor,applied either as monotherapy or in combination with other therapies as treatmentfor unresectable or metastatic cutaneous melanoma

• Patients with BRAF mutation should have been treated with one prior line ofBRAF-directed therapy (with or without a MEK inhibitor) prior to initial eligibilityassessment, unless deemed not clinically indicated at Investigator's discretion dueto concurrent medical condition, prior toxicity, or if declined by the patient

• Life expectancy more than 6 months

• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

• Female patient of childbearing potential must use adequate contraception fromrandomization until 12 months after the infusion of IMA203 or in line with theinstructions provided for investigator's choice treatment (in the control arm)

• Male patient must agree to use effective contraception or be abstinent while onstudy and for 6 months after the infusion of IMA203 or in line with the instructionsprovided for investigator's choice treatment (in the control arm)

• The patient must have recovered from any side effects of prior therapy to Grade 1 orlower prior to randomization.

Exclusion Criteria:

• Primary mucosal or uveal melanoma and melanoma of unknown primary

• History of other malignancies (except for adequately treated basal or squamous cellcarcinoma or carcinoma in situ) within the last 3 years

• Serious autoimmune disease Note: At the discretion of the investigator, thesepatients may be included if their disease is well controlled without the use ofimmunosuppressive agents.

• History of cardiac conditions as per protocol

• Prior allogenic stem cell transplantation or solid organ transplantation

• Concurrent severe and/or uncontrolled medical disease that could compromiseparticipation in the study

• History of or current immunodeficiency disease or prior treatment compromisingimmune function at the discretion of the treating physician

• History of hypersensitivity to CY, FLU, or IL-2 or presence of any contraindicationsand other limitations for planned treatment with investigator's choice as laid downin the current versions of the respective PIs / SmPCs

• Known hypersensitivity to any of the rescue medications

• History of or current immunodeficiency disease or prior treatment compromisingimmune function at the discretion of the investigator

• Positive for HIV infection or with active hepatitis B virus (HBV) or activehepatitis C virus (HCV) infection.

• Any condition contraindicating leukapheresis

• Pregnant or breastfeeding

• Any other condition that would, in the investigator's or sponsor's judgment,contraindicate the patient's participation in the clinical trial because of safetyconcerns or compliance with clinical trial procedures (e.g., psychiatric disordersor substance dependence, neurological impairment)

• Patient has received systemic corticosteroids within 2 weeks prior to leukapheresis,

• Patient has received surgery or other anti-cancer therapies, any agent that islikely to suppress bone marrow function, or investigational medicinal productswithin 7 days prior to leukapheresis.

• Patients with any active infection or ongoing reactivation of infection

• Patients who underwent non-myeloablative lymphodepletion prior to cell therapywithin the last 6 months

• Prior treatment with IMA203

• Patients with ascites, pleural or pericardial effusion which requires repeated (2within 4 weeks) or continuous paracentesis, thoracentesis or pericardiocentesiswithin last 2 months

• Patients with LDH greater than 2.0-fold ULN

• Concurrent treatment in another clinical trial or a device study that couldinterfere with the IMA203 treatment or planned investigator's choice treatment

• Patients with active brain metastases or leptomeningeal metastases

• Patient has received any investigational therapies, inactivated vaccines, chronicuse of systemic corticosteroids or IV antibiotics within 1 week prior torandomization, or live vaccines within 4 weeks prior to randomization

• Patient has received any anti-cancer therapy (prior anti-cancer treatment orbridging therapy) or radiotherapy within 1 week prior to start of trial treatment

• Other protocol defined inclusion/exclusion criteria could apply